All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1851-1857

  Coumans, F A W ^a   Doggen, C J M ^a   Attard, G ^b   de Bono, J S ^b   Terstappen, L W M M ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Castration resistant prostate cancer; Circulating tumor cell; Morphological appearance; Tumor microparticle

Indexed keywords

BICALUTAMIDE; CD45 ANTIGEN; CYTOKERATIN; DNA; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MITOXANTRONE; NILUTAMIDE;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATION TUMOR CELL; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTICENTER STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL;

EID: 77955082633     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq030     Document Type: Article

References (31)

1. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
2. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
3. Budd GT, Cristofanilli M, Ellis M et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6404-6409.
4. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells predict progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients. Clin Cancer Res 2006; 12: 4218-4224.
5. Cohen SJ, Punt CJA, Iannotti N et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
6. Olmos D, Arkenau HT, Ang JE et al. Circulating tumor cells (CTC) as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20: 27-37.
7. Tol J, Koopman M, Miller MC et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2009 doi:10.1093/annonc/mdp463.
8. De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC). Clin Cancer Res 2008; 14: 6302-6309.
9. Kagan M, Howard D, Bendele T et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Lig Assay 2002; 25: 104-110.
10. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
11. Rao CG, Chianese D, Doyle GV et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-58.
12. Tibbe AGJ, Miller C, Terstappen LWMM. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007; 71A: 154-162.
13. Larson CJ, Moreno JG, Pienta KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62A: 46-53.
14. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1241.
15. Pachmann K, Camara O, Kavallaris A et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26(8): 1208-1215.
16. Kahn HJ, Presta A, Yang LY et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat 2004; 86: 237-247.
17. Krivacic RT, Ladanyi A, Curry DN et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004; 101: 10501-10504.
18. Alix-Panabiéres C, Brouillet JP, Fabbro M et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005; 299: 177-188.
19. Schwarzenbach H, Alix-Panabières C, Müller I et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-1038.
20. Hsieh HB, Marrinucci D, Bethel K et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893-1899.
21. Racila E, Euhus D, Weiss AJ et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998; 95: 4589-4594.
22. Terstappen LWMM, Rao C, Gross S, Weiss A. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000; 17: 573-578.
23. Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-718.
24. Hayes DF, Walker TM, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-1118.
25. Harrell FE Jr.. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer 2001.
26. Swennenhuis JF, Tibbe AGJ, Levink R et al. Characterization of circulating tumor cells by fluorescence in-situ hybridization. Cytometry A 2009; 75A: 520-527.
27. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101: 9393-9398.
28. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
29. Meng S, Tripathy D, Frenkel EP et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A 2006; 103: 17361-17365.
30. de Bono JS, Attard G, Adjei A et al. Potential applications for circulating tumor cells expressing the insulin growth factor-I receptor. Clin Cancer Res 2007; 13: 3611-3616.
31. Smirnov DA, Zweitzig DR, Foulk BW et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005; 65: 4993-4997.